DNB Asset Management AS Makes New $397,000 Investment in Urogen Pharma $URGN

DNB Asset Management AS purchased a new position in shares of Urogen Pharma (NASDAQ:URGN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 16,961 shares of the company’s stock, valued at approximately $397,000.

Several other hedge funds have also recently added to or reduced their stakes in URGN. Osaic Holdings Inc. lifted its stake in Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after purchasing an additional 486 shares during the last quarter. State of Wyoming bought a new stake in Urogen Pharma during the third quarter worth about $66,000. Russell Investments Group Ltd. lifted its stake in Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares during the last quarter. Finally, Strs Ohio bought a new stake in Urogen Pharma during the third quarter worth about $76,000. Institutional investors own 91.29% of the company’s stock.

Wall Street Analyst Weigh In

URGN has been the subject of several research analyst reports. LADENBURG THALM/SH SH initiated coverage on Urogen Pharma in a research note on Monday, May 11th. They set a “buy” rating and a $43.00 price target for the company. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. D. Boral Capital reiterated a “buy” rating and issued a $33.00 price objective on shares of Urogen Pharma in a report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. Finally, Oppenheimer lifted their price objective on Urogen Pharma from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Urogen Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.67.

Urogen Pharma Trading Down 1.1%

URGN opened at $29.88 on Friday. The company has a market cap of $1.46 billion, a P/E ratio of -10.87 and a beta of 1.58. The business’s 50-day moving average price is $22.51 and its 200-day moving average price is $22.31. Urogen Pharma has a 12 month low of $3.61 and a 12 month high of $32.37.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to analysts’ expectations of $44.83 million. Equities research analysts forecast that Urogen Pharma will post -0.98 earnings per share for the current fiscal year.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.